Optimal Hemodynamics and Risk of Severe Outcomes Post-Left Ventricular Assist Device Implantation. Issue 3 (March 2022)

• Record Type: Journal Article
• Authors: Rosenbaum, Andrew N.; Ternus, Bradley W.; Stulak, John M.; Clavell, Alfredo L.; Schettle, Sarah D.; Behfar, Atta; Jentzer, Jacob C.
• Is Part Of: ASAIO journal. Volume 68:Issue 3(2022)
• Publication Date: 2022-03
• Subjects: left ventricular assist device -- LVAD -- optimization -- hemodynamics -- right ventricular failure -- dialysis -- Outcomes; Artificial organs -- Periodicals; 617
• DOI: 10.1097/MAT.0000000000001465
• Languages: English
• ISSNs: 1058-2916

Abstract

Abstract : Data on pre-implant hemodynamic optimization before continuous flow left ventricular assist device placement (CF-LVAD) with respect to patient-centered outcomes remain limited. Consecutive patients undergoing CF-LVAD implant between 2007 and 2017 were identified. Hemodynamic variables, trends, and laboratory studies were evaluated pre-LVAD implant in a logistic regression model to identify predictors of the primary composite endpoint: the need for right ventricular assist device therapy, the requirement for hemodialysis at 90 days, and 30-day mortality. Multivariate modeling identified three variables significantly associated with the primary endpoint: right ventricular stroke work index (RVSWI), right atrial pressure (RAP), and blood urea nitrogen (BUN); all immediately pre-LVAD, p < 0.01. Optimal dichotomization points were 500 mmHg*ml*m −2, 12 mmHg, and 40 mg/dL. The three-component model identified an AUC of 0.77 ( p < 0.0001) for the composite endpoint. Optimization of 2/3 parameters, 1/3, and 0/3 was associated with odds ratios of 3.5 (95% CI, 1.1−11.7), 7.2 (95% CI, 2.1−24.2), and 20.6 (95% CI, 5.3−80.6), respectively, relative to those patients who were fully optimized (3/3 parameters). The number of optimized parameters was also associated with 1-year overall survival ( p = 0.02). Low RVSWI, high RAP, and high BUN were independently associated with adverse outcomes after the CF-LVAD implant, demonstrating a stepwise association with severe postimplant adverse events.